key: cord-0987995-hzi7mpbm
authors: Sun, Shiyu; Cai, Yueqi; Song, Tian-Zhang; Pu, Yang; Cheng, Lin; Xu, Hairong; Meng, Chaoyang; Lin, Yifan; Sun, Jing; Zhang, Silin; Gao, Yu; Han, Jian-Bao; Feng, Xiao-Li; Yu, Dan-Dan; Zhu, Yalan; Gao, Pu; Tang, Haidong; Zhao, Jincun; Zhang, Zheng; Yang, Jiaming; Hu, Zenxiang; Fu, Yang-Xin; Zheng, Yong-Tang; Peng, Hua
title: Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
date: 2021-05-12
journal: bioRxiv
DOI: 10.1101/2021.05.12.443228
sha: 383312adb0f23293544b768aee1523e69b1be403
doc_id: 987995
cord_uid: hzi7mpbm

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global crisis, urgently necessitating the development of safe, efficacious, convenient-to-store, and low-cost vaccine options. A major challenge is that the receptor-binding domain (RBD)-only vaccine fails to trigger long-lasting protective immunity if used solely for vaccination. To enhance antigen processing and cross-presentation in draining lymph nodes (DLNs), we developed an interferon (IFN)-armed RBD dimerized by immunoglobulin fragment (I-R-F). I-R-F efficiently directs immunity against RBD to DLN. A low dose of I-R-F induces not only high titer long-lasting neutralizing antibodies but also comprehensive T cell responses than RBD, and even provides comprehensive protection in one dose without adjuvant. This study shows that the I-R-F vaccine provides rapid and complete protection throughout upper and lower respiratory tracts against high dose SARS-CoV-2 challenge in rhesus macaques. Due to its potency and safety, this engineered vaccine may become one of the next-generation vaccine candidates in the global race to defeat COVID-19.

while CD4 + T cells in RBD vaccinated groups produced none of these cytokines, similarly as that in the 199 unimmunized group (Fig. 3f and extended Data Fig. 2e ). To determine if CD8 + T cells respond to viral-200 specific RBD, the intracellular cytokine staining was performed to determine the proportion of producing CD8 + T cells after stimulation with the RBD peptide pool. Notably, I-R-F induced a much 202 higher number of cytokine-producing CD8+ T cells in vaccinated mice, suggesting that poor 203 immunogenicity of RBD may not result from lacking the proper T and B cell epitopes ( Fig. 3g and  204 extended Data Fig. 2f) . Therefore, I-R-F can induce potent and comprehensive T-and B-cell responses, 205 addressing the main challenge for protein-based COVID-19 vaccines. 206 207 208 We hypothesize that the more robust immune responses induced by I-R-F compared to RBD might be 209 attributed to the fused dimerized Fc, which improves draining to LN. To demonstrate this hypothesis, 210 we labeled RBD and I-R-F protein with fluorescein. After subcutaneous injection at the tail base, 211 bilateral inguinal LN were isolated at different hours post injection. A significantly increased intensity 212 of fluorescence in the I-R-F group was observed from 6 hours to 24 hours post injection, with the 213 maximum difference shown at 12 hours (P-value < 0.0001) ( Figure. 4a and 4b) . Fluorescein labeled 214 RBD failed to reach LN effectively, likely due to its smaller molecular size. In consideration of different 215 labeling efficiency across different proteins, which may influence the quantitative analysis of 216 fluorescent molecules, we replaced RBD with eGFP (enhanced green fluorescent protein) to generate 217 IFNα-eGFP-Fc fusion protein (I-E-F). In order to assure consistency with the recommended 218 immunization pathway, we intramuscularly injected equal moles of eGFP and I-E-F in the lateral thigh 219 of mice. We analyzed eGFP + myeloid cells in isolated DLN by flow cytometry. The percentages of eGFP 220 positive dendritic cells (DCs) ( Fig. 4c and 4d ) and macrophages in I-E-F vaccinated mice were 221 remarkably higher (Extended Data Fig. 3a and extended Data Fig. 3b ) than that in the eGFP alone 222 group. These data suggest that I-R-F is likely to target LN much more efficiently than RBD. To directly 223 examine the maturation of DCs, likely resulting from IFNα stimulation, the expression of CD80 and 224 CD86 in the I-R-F group was determined by flow cytometry. Compared to RBD, the I-R-F group 225 presented much higher levels of CD80 and CD86 on DCs ( Fig. 4e and Extended Data Fig. 3c) . 226 Effective generation of T follicular helper cells (Tfh) could result from better antigen presentation to 227 CD4 + T cells. Tfh in lymphatics tissues are essential for forming germinal centers (GC) and 228 differentiation of B cells 30, 31 . We also found the increased percentage and number of total GC B cells 229 in the I-R-F group than in the RBD group (P <0.001). Also, a higher percentage and more Tfh cells were 231 detected in inguinal LNs. Characterization of antigen-specific Tfh cells is essential to define the 232 mechanistic basis of antibody responses. Further, an assay of activation-induced markers (AIM) was 233 performed, showing that more RBD-specific Tfh cells were induced in I-R-F than the RBD group ( Fig. 4j and extended Data Fig. 3f ). Together, these data suggest that I-R-F can target and activate DC in LN 235 more efficiently than RBD, leading to stronger Tfh and GC reactions. 236

The pan DR epitope(Pan)further enhances the immunogenicity of I-R-F vaccine 238 To avoid the potential limitation and competition with RBD immunogenicity from dominant epitopes 239 outside RBD in the S glycoprotein, we selected RBD-dimer as the only viral antigen. However, RBD, 240 a smaller polypeptide portion of S protein, might contain a limited number of helper T cell epitopes to 241 B cells and CTL in a broader population. The pan DR-binding epitope (PADRE) is known to provide 242 broad T cell help via binding to common human HLA-DR types and mouse IA b 32, 33 . To reduce the risk 243 of limited helper epitope for some HLA-DR, we inserted PADRE into I-R-F and constructed the I-P-R-244 F vaccine to augment T cell responses (the schematic model in Extended Data Fig. 4a) . A clear peak of 245 intact I-P-R-F fusion protein was visualized using size exclusion chromatography after a one-step 246 protein-A column purification (Extended Data Fig. 4b ). Additional SDS-PAGE also confirmed the 247 purity of this fusion protein (Extended Data Fig. 4b ). Real-time binding kinetics showed the high-248 affinity binding of I-R-F to hACE2, determined by the BIAcore T100 system (Extended Data Fig. 4c) . 249 The bioactivity of IFNα in I-P-R-F is as high as the free IFNα molecule measured by an anti-viral 250 infection biological assay (Extended Data Fig. 4d ). The mice were vaccinated i.m. with a low dose of 251 the indicated vaccines (0.1 μg). We observed an over 10-fold increase of antibody level in mice 252 immunized with I-P-R-F than I-R-F (Fig. 5a) . The neutralization activity in the anti-sera from 253 vaccinated mice was also evaluated using a pseudovirus neutralization assay. Consistently, mouse I-P-254 R-F resulted in up to 10-fold higher levels of neutralizing antibody at a notably low dose (Fig. 5b) . We 255 also generated a human I-R-F and a human I-P-R-F with a site-mutation (Q124R) on IFNα featuring 256 an increased binding affinity of human IFNα to mouse IFNα receptor and thus allow this human 257 IFN to be functional in the mouse model 34 . Higher antibody titers in immunized mouse sera were 258 induced by human IFNα-RBD-Fc than RBD-Fc, confirming the potency of human IFN in the mouse 259 model. Furthermore, human IFNα-Pan-RBD-Fc triggered a much higher antibody response to RBD 260 than human IFNα-RBD-Fc, which confirmed the role of Pan in enhancing the immunogenicity of poor 261 antigen (Fig. 5c) . 262

Rhesus macaque is a commonly used model for SARS-CoV-2 virology, pathology, immunology studies 265 and screening anti-virus vaccines and medicines. To investigate the immunogenicity of this newly 266 designed vaccine in rhesus macaques, eight macaques into four groups with a male and a female in each 267 group and i.m. immunized twice on day 0 and day 14, with either 10 μg or 50 μg V0-1 (human I-P-268 R-F), mixed with or without alum-adjuvant. Impressively, all vaccinated groups generated very high 269 levels of RBD-specific IgG antibodies, even with low-dose vaccination. High titer of antibody could be 270 induced in macaques even by vaccine without adjuvant no matter high or low vaccine doses (Extended 271 Data Fig. 5a and 5b) . Importantly, the high titer anti-virus IgG has been maintained for 250 days so far. 272

The sera from vaccinated animals were subjected to neutralization assays with pseudovirus and 273 authentic SARS-CoV-2 (Extended Data Fig. 5c and 5d ). The high viral neutralization titers (NT50>1000 274 and FRNT50>3000, respectively) indicate that this newly designed vaccine could induce strong and 275 long-lasting protective immunity. 276 To further study if the vaccine has a protective effect, eighteen rhesus macaques were divided into 277 three groups (6 per group) and vaccinated twice (day 0/14) with 10 μg or 50 μg alum-adjuvanted V0- 1, 278 or alum alone as a control, respectively. All immunization was done via the i.m. injection in the lateral 279 thigh. Macaques were challenged with a high dose of SARS-CoV-2 (1×10 7 TCID50) intranasally 21 days 280 after the initial immunization. We observed very high titers of antibody against RBD in both low-and 281 high-dose vaccinated groups as determined by ELISA (Fig. 6a) . It is noteworthy that high titers of 282 neutralizing antibody were presented in both low-and high-dose vaccinated groups as determined by 283 pseudovirus and live virus neutralization assays ( Fig. 6b and Extended Data Fig. 5e ). Although disease 284 symptoms for SARS-CoV2 infection are rather mild in Rhesus macaques, when monkeys were infected 285 with a high dose of viruses, body temperature was higher in the control group (Fig. 6c ), as measured 286 every two days after virus challenge. Similarly, lower body weight was observed in the control group 287 but not observed in the immunized group at all (Fig. 6d) . 288 Virus clearance in the upper respiratory tract in rhesus macaques has rarely been reported during 289 the first seven days of infection, even after potent vaccination. However, our vaccine resulted in a 290 significant reduction of viral loads in the nasal passages of macaques in the low dose-vaccine group and 291 even undetectable viral load in the high dose-vaccine group only one day after high titer virus infection, 292 as determined by sensitive qPCR (Fig. 6e) . Similarly, viral loads in tracheal brushes were also 293 undetected in both the low-and high-dose vaccinated groups one day after virus infection (Fig. 6f) . 294 Viral loads in anal swabs of rhesus macaques were undetectable one day after infection in both the low-295 and high-dose vaccinated groups (Extended Data Fig. 5f ). For each group of vaccinated macaques, 84 296 specimens from lung lobes (14 samples/7 lobes/mice) were collected on day 7 post infection and subjected to determine the viral loads in all areas of lung lobes by q-PCR. Over an average of 4 log 298 reduction of virus load was observed in the lungs of both low-and high-dose of vaccinated groups, 299 while extremely high viral loads were maintained in the lungs of control macaques ( Fig. 6g and  300 Extended Data Fig. 5g ). These data demonstrate that V0-1 can generate highly effective protection 301 against SARS-CoV-2 infection in both upper and lower respiratory tracts even with low-dose 302 vaccination. 303 A Randomized, double-blind, placebo-controlled phase I clinical trial was initiated on Feb 24, 2021 304 to evaluate the safety and immunogenicity of recombinant SARS-Cov-2 fusion protein vaccine (V-01) 305 in healthy subjects (Phase I: ChiCTC2100045108; phase II: ChiCTR2100045107). The study was a 306 single-center clinical trial, in which healthy subjects aged 18 and above were divided into 120 for 307 treatment while 30 for placebo) were given two doses of recombinant SARS-CoV-2 fusion protein 308 vaccine (V-01) or placebo on days 0 and 21, respectively. All the AEs reported in each group within 309 seven days after dosing of 10, 25, and 50 μg. The first-dose vaccination, safety follow-up on day 7 310 and a follow-up in all adult subjects were completed. All AEs of grade 1 (23.33%) were observed within 311 seven days after dosing, and all the remaining AEs were of grade 2 (3.33%). There were no AEs or 312

SAEs of grade ≥3 that were related to the investigational vaccine. All adults from 18-60 had positive 313 for antibody to RBD. The observation is still ongoing. Multiple types of SARS-CoV-2 vaccines have been developed and entered into clinical trials in an 319 endless stream. Immunological effects and safety of these vaccines have been reported 16, 17, [42] [43] [44] . An 320 ideal vaccine should have the following properties: 1) efficacy and safety, presented by high titer 321 neutralizing antibodies and T cell responses with no toxicity and antibody-dependent enhancement 322 (ADE); 2) prolonged protective immunity and easy administration; 3) "simplified" large-scale 323 production, storage, and distribution. Here, we designed and evaluated a vaccine platform based on 324 IFN-α armed RBD, a dimerized human IgG1 Fc (I-R-F) molecule. Evidenced by the results on mice and 325 rhesus macaques, the I-R-F vaccine may provide an effective prophylactic solution for COVID-19. Because 326 1) Potency: Due to its size, IFN-armed RBD dimerized by Fc will primarily target to DLN and increase 327 antigen processing and presentation inside DLN. Therefore, hundreds to thousands fold more 328 neutralizing RBD-specific IgG1 and IgG2a antibodies were induced by I-R-F than monomer RBD. In 329 addition, Th1, Th2, and CD8 + T cell responses could be readily detected after vaccination; 2) Safety: 330 RBD is the only exogenous antigen in the vaccine; thus, all antibodies induced are targeting RBD to 331 block viral entry. I-R-F could be elicit robust and long-lasting immune responses at a low dose (0.01 332 ug) or even without adjuvant. Unlike smaller molecule of free IFN (18.7), much higher molecule weight 333 of I-R-F will allow this molecule to flow into DLN to improve antigen presentation and DC mature. 334

Alum adjuvant used in this vaccine is well known and widely used without severe toxicity. Furthermore, 335 alum-adjuvanted I-R-F allows slow release of I-R-F molecule into DLNs, resulting in prolonged, 336 effective, and safe immune challenges inside DLNs. On the other hand, there were no detectable 337 autoimmune B or T cell responses to IFN. 3) Durability：The level of neutralizing antibodies induced 338 by I-R-F vaccine was maintained for more than 250 days in the rhesus macaque model; 4) Accessibility: 339 fusion with Fc is easy for large-scale manufacturing and purification. High productive clones (one gram 340 level per liter) for large scale human I-P-R-F (V-01) production of have been confirmed in GMP grade 341 manufacturing; 5) Portability：this fusion protein is stable at 4-25 o C for months, which notably allows 342 for more accessible transport and storage for developing countries. 343 A potential hurdle of ADE induced by antibodies with weak neutralizing activities should be 344 considered in developing the SARS-CoV-2 vaccine 45 . COVID-19 patients with higher antibody titers 345 against SARS-CoV-2 may be associated with more severe illness, though the mechanism is still not 346 fully determined 46 . Subunit vaccines have been proposed to focus on S or RBD protein inducing the 347 neutralizing antibodies to avoid producing ineffective antibodies and reduce ADE. However, 348 monomeric RBD is a weak immunogenic antigen, and multiple immunizations are needed for acquiring 349 protective immunity 11 . To enhance immunogenicity, either modified S or RBD, such as S-trimer and 350 RBD-dimer proteins, were developed, which help to mimic the native 3D conformation of oligomerized 351 S protein in vivo 5, 47 , or forming protein nanoparticles by displaying the RBD 48, 49 . However, the large-352 scale productions of those new adjuvants remain challenged. Additionally, RBD fused with the Fc 353 domain could also be a better choice than simple RBD or S protein 7-9 . With equivalent molar, both I-R-354 F and I-P-R-F induced stronger humoral immunity than RBD-Dimer and RBD-Fc. In general, protein 355 vaccines could not have enough protective immunogenicity without additional potent adjuvants. IFN 356 can provide an adjuvant effect with undetectable toxicity while enhancing immunogenicity and antigen 357 presentation. 358 For protein vaccines, Th1 or Th2 responses are mainly dependent on types of adjuvants. Notably, 359 enhanced immunopathology was associated with a Th2-biased response 10, 50-52 . The choice of adjuvant 360 is thus a crucial point to solve the problem. Alum is a universal adjuvant accompanied with protein 361 vaccines leading to high antibody titers, while it always induces Th2-biased response 53 . Moreover, 362 weak or even no CD8 + T cell responses could be elicited by protein-based vaccines. All these drawbacks 363 make protein vaccines undesired for the ideal and effective vaccine candidates. Herein, we designed an 364 I-R-F vaccine with extremely strong immunogenicity even at a minuscule dose or without adjuvant. 365 Mechanistically, multiple factors contribute to such robust immune responses. 1) IFNα is the most 366 potent cytokine for antigen processing and presentation of DC 54 . With I-R-F, we have observed more 367 efficient antigen uptake by DCs; 2) IFN-α could also be used as an adjuvant in improving the generation 368 of Tfh 55 . We found that the I-R-F vaccine induced higher percentages of Tfh and GC B cells, as well 369 as both high RBD-specific IgG1 and IgG2a titers indicating strong humoral immunity. Moreover, IFN 370 might help Th1 and CTL responses even with alum. Indeed, the I-R-F vaccine could transfer the 371 aluminum-induced Th2-biased response to a more robust Th1-Th2 balanced response. 3) Importantly, 372

The Pan epitope further enhances the I-R-F vaccine-induced robust CD4+ and CD8 + T cell responses 373 that contribute to eliminating virus-infected cells; 4) The additional Fc can allow RBD form dimer 374 naturally and make I-R-F to become a much bigger molecule than RBD, to get to DLNs more efficiently. 375 High doses and long-term use of various formats of type I interferon have been approved for several 376 viral infections, but some patients showed various toxicities 56-58 . No significant body weight loss or 377 abnormal ALT/AST above background was observed after vaccination for preclinical studies. There 378 was no significantly increased cytokines induced by the vaccine at the tested doses. We have not 379 observed any sign or symptom from I-R-F vaccinated host. 380

In the light of significant immunogenicity, complete protection efficiency in both upper and lower 381 respiratory tract, and undetectable toxicity of I-P-R-F in macaques, this unique protein vaccine can be 382 potentially used in very low dosage and merely single vaccination. Furthermore, this protein vaccine 383 maintains its potency even without adjuvant, which may provide a good chance for intranasal 384 vaccination in all ages, especially young children. Nasal I-R-F vaccine investigations are underway 385 since it could trigger mucosal IgA response to prevent the virus from invading mucosa in nose and 386 upper respiratory tract or infecting others. Armed-IFN that overcomes poor immunogenicity of some 387 antigens can be applied broadly to prevent other infectious diseases during future pandemics. This enhanced immunogenicity by new design is not limited to protein vaccine and could also be applied to 389 other vaccine forms, such as genetic or viral-vector-based vaccines. substituting for murine IFNα4, I-P-R-F (human) were expressed and purified with the same method as 452 described above. 453 SARS-CoV-2 RBD protein (rRBD) was also expressed in 293F cells. In brief, the coding sequence for 454 RBD with a 6 x his tag on C terminus was cloned into the pEE12.4 vector without a human IgG1 Fc. 455 The plasmid was transiently transfected into 293F cells. The supernatant was harvest on day 7, and the 456 protein was purified using Ni-NTA agarose beads (GE Healthcare). The protein was further purified on 457 a Superdex 200 Increase 10/300 GL size exclusion column (GE Healthcare). SDS-PAGE was performed 458 to determine the purity and size of the protein. The eGFP and dimer-RBD protein were expressed and 459 purified in the same method as rRBD. 460

Surface plasmon resonance assays were performed by a BIAcore T100 instrument with a CM5 sensor 462 chip (GE Healthcare). Experiments were carried out at 25℃ in binding buffer (PBS, 0.05% Tween 20, 463 pH 7.4). The CM5 sensor chip was used to capture about 100 response units (RUs) The RBD of SARS-464

IFNα-Pan-RBD-Fc for 3 min respectively. A two-fold serial dilution of hACE2 (from 6.25nM to 200nM) 466 were run across the chip surface with a flow rate of 30μl /min, and the real-time response was recorded. 467

The resulting data were analyzed fitting to a 1:1 binding model with Biacore Evaluation Software. 468

The IFNα bioactivity was determined by the anti-viral infection assay using the L929 fibroblast cell 

The immunogen used to immunize mice was diluted with PBS and mixed with or without a fixed-dose 478 (20ug per mouse) of alum adjuvant (SEVA, Germany). To make alum adsorb the immunogen efficiently, 479 the mixture was kept rolling overnight at 4℃. Female (6-8-week-old) BALB/c or C57BL/6 mice were 480 immunized intramuscularly or subcutaneously with different immunogens in 100μL using insulin 481 syringes. PBS containing alum was used as control. Sera were collected at indicated time points to 482 determine the levels of SARS-CoV-2 RBD specific IgG and neutralization antibody. The detail of 483 mouse vaccination was described in figure legends. 484

The 96-well plates (Conning, USA) were coated with 100ul SARS-Cov-2 RBD (1.5ug/ml) overnight at 486 4℃. Plates were washed with PBS and blocked with a blocking buffer (PBS containing 5% fetal bovine 487 serum, FBS) on the next day. Immunized animal serum samples were serially diluted and added into 488 the blocked plates, followed by incubation at 37℃ for 1 hour. Plates were then washed with PBST (PBS 489 containing 0.05% Tween 20) and incubated with goat anti-mouse IgG-HRP (1:5000, Cwbiotech) or goat 490 anti-monkey IgG-HRP (1:10000, Invitrogen) at 37℃ for 30 minutes. To detect the Ig subclasses, goat 491 anti-mouse IgG1 (1:5000, Proteintech), goat anti-mouse IgG2a (1:5000, Proteintech) were added. Plates 492 were washed with PBST, and HRP substrate TMB was added. The reactions were stopped by 2M 493 sulfuric acid. The absorbance at 450-630 was read using a microplate reader (Molecular Devices). The endpoint titers were defined as the reciprocal of max serum dilution at which the absorbance was higher 495 than 2.5-fold of the background. 496

The pseudovirus neutralization was carried out as described previously. In brief, the pseudovirus was 498 produced by co-transfection of the plasmid expressing firefly luciferase (pNL43R-E-luciferase) and 499 pcDNA3.1 expressing the SARS-CoV-2 spike protein into 293T cells. After 48 hours, the viral 500 supernatant was collected, and viral titers were determined by luciferase activity in relative light units. 501

To evaluate the neutralization of vaccinated mice serum, 293-hACE2 cells were seeded into 96-well 502 plates (2x10 4 per well) and 3-fold serially diluted heat-inactivated serum samples were incubated with 503 100 TCID50 of pseudovirus for 1 hour at 37℃. Medium mixed with pseudovirus was given as control. 504 The mixture was transferred to the 96-well plates, and the platers were continued to incubate for another 505 24 hours. According to the manufacture ' s instruction, the luciferase substrate was added, and luciferase 506 activity was determined by the Bright-Lite TM Luciferase Assay System (Vazyme). The 50% 507 neutralization titer (NT50) was defined as the reciprocal of serum dilution at which the relative light 508 units (RUL) were reduced by 50% compared with virus control wells. 509

Vero-E6 cells were seed into 96-well plates with a density of 2x10 4 per well. Sera from immunized 511 animals and convalescent COVID-19 patients were serially diluted and mixed with 75 µl of authentic 512 SARS-CoV-2 (8 × 10 3 focus-forming units (FFU)/ml)). The mixture was incubated for 1 hour at 37℃ 513 and then transferred to the 96-well plates seeded with Vero E6 cells. Plates were incubated for 1 hour 514 at 37℃. The inoculums were removed, and the plates were overlaid with medium (100 µl DMEM 515 containing 1.6% carboxymethylcellulose, CMC). The plates were incubated for another 24 hours at 516 37℃. The supernatant was removed, and cells were fixed with 4% Paraformaldehyde for 30 min. Cells 517 were subsequently permeabilized with PBS containing 0.2% Triton X-100. After PBS washing for three 518 times, the cells were incubated with cross-reactive rabbit anti-SARS-CoV-2 nucleocapsid IgG (Sino 519 Biological) for 1 hour at 37°C. After incubated with the primary antibody, plates were washed three 520 times with PBST before adding the second antibody, HRP-conjugated goat anti-rabbit IgG (Jackson 521 ImmunoReseach). Cells were further incubated for 1 hour at 37°C. After washing, the KPL TrueBlue 522 peroxidase substrates (Seracare Life Science) were added to the plates. The supernatant was removed, 523 and the plates were washed three times with deionized water five minutes later. The numbers of SARS-524

CoV-2 foci were read using an ELISPOT reader (Cellular Technology). The FRNT50 was defined as the 525 sera dilution at which neutralization antibodies inhibited 50% of the viral infection. 526

Vero-E6 cells were harvested and seeded into 96-wells plates with 2×10 4 cells per well and cultured at 528 37℃ overnight. The Serum samples from immunized Rhesus Macaques were inactivated at 56℃ for 529 30 minutes and serially diluted with cell culture in 3-fold steps. The diluted serum samples were mixed 530 with a virus suspension containing 100 TCID50 authentic SARS-CoV-2 in an equal volume. After 531 neutralization in a 37℃ incubator for 1 hour, the mixtures were transferred to the 96-well plates 532 containing Vero-E6 cells. Inoculated plates were cultured in a CO2 incubator at 37℃ for 6 days. 533 Cytopathic effect (CPE) of each well was scored, and the neutralization titer was calculated as the 534 reciprocal of serum dilution at which neutralization antibodies inhibited 50% of viral infection. 535

Murine IFNγ and IL-4 ELISPOT assays were carried out according to the manufacture ' s protocols for 537 mouse IFNγ and IL-4 ELISPOT kit (BD Bioscience). Immunized mice splenocytes were seeded in the 538 plates with a density of 2 × 10 5 cells per well and incubated with the peptide pool of 15 mer peptides 539 with 11 overlapping amino acids for SARS-CoV-2 RBD protein (5 μg/mL) in pre-coated 96-well 540 ELISPOT plates with IFNα or IL-4, Concanavalin A (ConA, Sigma) as a positive control or medium as 541 a negative control for 48 hours at 37℃. Then, the cells were removed, and biotinylated IFN-γ or IL-4 542 (BD Bioscience) was added to the plates, followed by incubation for 2 hours at room temperature. The 543 plates were washed three times with PBST before adding Streptavidin-HRP (BD Bioscience). The BD 544 ELISPOT AEC substrate (BD Bioscience) was used to develop the spots. Spots were counted and 545 analyzed using an automated ELOSPOT reader (Cellular Technology). For B cell ELISPOT assay, 546 splenocytes from immunized mice were seeded in the plate coating with 2.5 μg/mL RBD protein. Cells 547 were removed 16 hours post incubation, and biotinylated goat anti-mouse IgG (BBI life sciences) was 548 added into plates, followed by incubation for 2 hours at room temperature. The plates were washed 549 three times with PBST before adding Streptavidin-HRP (BD Bioscience). The BD ELISPOT AEC 550 substrate (BD Bioscience) was used to develop the spots. Spots were counted and analyzed using an 551 automated ELOSPOT reader (Cellular Technology). 552

To evaluate the cytokine expression in antigen-specific T cells, Intracellular cytokine staining (ICCS) 554 assay was performed. Mouse splenocytes were seeded in U-bottom 96-well plates (1x106/well) and 555 stimulated with a peptide pool for SARS-CoV-2 RBD protein as described above. After 12-hour 556 stimulation, Brefeldin A (Biolegend) was added, and the cells were collected, and first stained with anti-557 CD3 (Biolegend), anti-CD4 (Biolegend), anti-CD8 (Biolegend) and the LIVE/DEADTM dyes before 558 fixed and permeabilized using a fixation/permeabilization kit (BD bioscience). The cells were 559 subsequently performed with intracellular staining for IFN-γ (XMG1.2), IL-2 (JES6-5H4), TNF-α 560 (MP6XT22)，IL-4 (11B11). The cells were acquired using a FACS Fortessa flow cytometer (BD 561 Bioscience) and analyzed with Flowjo software (TreeStar). 562

In vivo imaging analysis 563 BALB/c mice were subcutaneously injected with 0.1 µmol (cy5.5) of different cy5.5-labeled proteins 564 (RBD, I-R-F) at the tail base. The inguinal LNs were extracted for imaging DLN and were imaged at 565 indicated time points post injection using an in vivo imaging system (IVIS) Spectrum (PerkinElmer). 566

The fluorescence imaging data were analyzed by Living Image software (PerkinElmer). 567

The DLNs were excised and digested into a single-cell suspension. To evaluate the immunogenicity of I-P-R-F in non-human primates, a total of 10 rhesus macaques (5 580 male and 5 female, weighing 3~5 kg) purchased from Guangxi Fangchenggang Biotechnology 581 Development Co., Ltd. were randomly assigned into four groups with one male and one female in each 582 group and intramuscularly immunized with high does(50 µg) or low dose(10 µg) of I-P-R-F with or 583 without alum as adjuvant two times at a 14-day interval. Blood was collected at indicated time points, 584 and the SARS-CoV-2 specific IgG and neutralization antibody titers in serum were determined. 585

A total of 18 Rhesus macaques (3-5-year old) were recruited and assigned into three groups. Macaques 587 in group 1 were intramuscularly immunized with PBS formulated with the alum-adjuvant as control. 588

Group 2 and Group 3 were vaccinated with 50 µg (high dose) or 10 µg (low dose) of I-P-R-F. Animals 589 received a two-dose immunization procedure on day 0 and day 14 after the initial vaccination. The 590 macaques were intranasally challenged with 10 7 TCID50 of SARS-CoV-2 seven days after the second 591 immunization. Animal body temperature and body weight were recorded after the virus challenge. An unpaired student's two-tailed t-test was used to determine statistical significance for comparison 609 between two groups. One-way ANOVA with Turkey's multiple comparison test or two-way ANOVA 610 with Turkey's multiple comparisons test was conducted to compare differences among multiple groups. Extended Data Figure 6 

A Novel Coronavirus from Patients with Pneumonia in China

Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected 639 hamsters and provides a potent cocktail pairing strategy

Development of an inactivated vaccine candidate for SARS-CoV-2

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent 642 Protection against SARS-CoV-2

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and 644 SARS

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific 646

Recombinant Fc-fusion vaccine of RBD induced protection against SARS-CoV-2 in 649 non-human primate and mice

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike 653 receptor binding domain Fc fusion protein in mice

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits 655 immunogenicity in baboons and protection in mice

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput 657 single-cell sequencing of convalescent patients' B cells

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 659 pneumonia in rhesus macaques

Safety and immunogenicity of a recombinant adenovirus type-5 vector-661

based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-662 controlled, phase 2 trial

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in 666 Nonhuman Primates

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in 670 adults

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal 672 Efficacy Study. medRxiv : the preprint server for health sciences

Development of high potency universal DR-restricted helper 674 epitopes by modification of high affinity DR-blocking peptides

Dynamics and function of langerhans cells in vivo: dermal dendritic 676 cells colonize lymph node areasdistinct from slower migrating langerhans cells

Normal structure, function, and histology of lymph nodes

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses 679 to overcome checkpoint blockade resistance

SARS-CoV-2 neutralizing antibody structures inform therapeutic 681 strategies

An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 683 receptor binding domain

IFN-α as an Adjuvant for Adenovirus-Vectored FMDV Subunit 685 Vaccine through Improving the Generation of T Follicular Helper Cells

How) do aluminium adjuvants work?

Mechanisms of stimulation of the immune response by aluminum adjuvants

Interleukin-12 profoundly up-regulates the synthesis of 690 antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo

Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype 692 production

Follicular helper T cells: lineage and 694 location

Germinal center B cell and T follicular helper cell development initiates 696 in the interfollicular zone

Prototype Alzheimer's disease vaccine using the 698

immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

The optimization of helper T lymphocyte (HTL) function in vaccine 701 development

Single amino acid changes that render human 703 IFN-alpha 2 biologically active on mouse cells

The high infectivity of SARS-CoV-2 B. 1.1. 7 is associated with increased interaction 705 force between Spike-ACE2 caused by the viral N501Y mutation

Increased elastase sensitivity and decreased 707 intramolecular interactions in the more transmissible SARS-CoV-2 variants' spike protein

Multiple SARS-CoV-2 variants escape neutralization by vaccine-709 induced humoral immunity

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-711 elicited human sera

SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies 713 Elicited by Ancestral Spike Vaccines

mRNA-1273 vaccine induces neutralizing antibodies 715 against spike mutants from global SARS-CoV-2 variants

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to 717 convalescent sera and monoclonal antibodies

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine 719 in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The 720 Lancet Infectious diseases

Immunogenicity and safety of a recombinant adenovirus type-5-vectored 722

COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, 723 phase 2 trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against 725

a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Clinical infectious diseases : an official publication of the Infectious Diseases Society of

NVX-CoV2373 vaccine protects cynomolgus macaque upper and 733 lower airways against SARS-CoV-2 challenge

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for 735 SARS-CoV-2

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad 737

Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses -ScienceDirect

A pneumonia outbreak associated with a new coronavirus of probable bat 739 origin

Immunization with SARS coronavirus vaccines leads to 741 pulmonary immunopathology on challenge with the SARS virus

Vaccine efficacy in senescent mice challenged with recombinant SARS-743

CoV bearing epidemic and zoonotic spike variants

The Common vaccine adjuvant aluminum hydroxide 745 up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism

Type I IFNs enhance the terminal differentiation of dendritic cells

IFN-α as an Adjuvant for Adenovirus

Subunit Vaccine through Improving the Generation of T Follicular Helper Cells

Naturally occurring anti-interferon-α2a antibodies in patients with 752 acute viral hepatitis

Mechanisms and management of toxicities associated with high-754 dose interferon alfa-2b therapy

Anti-756 interferon alpha antibodies and autoantibodies in patients with Behcet's disease uveitis treated with recombinant 757 human interferon alpha-2a

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating 759

CD8+ T-cell response and effective tumor control

were immunized with 10 μg of I-R-F, equimolar RBD, or PBS twice in a 14-day interval. PBS was performed 820 as a negative control. Sera were collected on day 28 after the initial immunization and used to determine the 821 IgG subclasses. (d-g) C57BL/6 mice were immunized with 10 μg I-R-F, equimolar RBD, or PBS with a 822prime-boost vaccination regimen in a 14-day interval. Mice were sacrificed, and splenocytes were collected 823 28 days post the first vaccination. ELISPOT assay was performed for IFN-γ (d) and IL-4 (e) secretion from 824 mice splenocytes stimulated with RBD peptide pool. Splenocytes were incubated with an RBD peptide pool. 825(f) The percentages of IFN-γ + , IL-4 + , and TNF-α + CD4 + T cells were determined by ICCS. (g) The 826percentages of IFN-γ + , IL-2 + , and TNF-α + CD8 + T cells were determined by ICCS. The dashed